FDA grants Bayer accelerated review for radium-223 dichloride

02/19/2013 | Fox Business · OncLive

The FDA has given priority review status to Bayer's radium-223 dichloride, used to treat prostate cancer. The designation will cut several months from the usual review timeline. The company is seeking approval for use of the drug in patients with castration-resistant prostate cancer that has spread to bone.

View Full Article in:

Fox Business · OncLive

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN